About
Our vision
Scientists have discovered a fundamental aspect of cell biology, resulting in the creation of an entirely new field of research focused on ‘exosomes’.
Technically exosomes are but one category in the field known in a broader sense as extracellular vesicles. Now, exploring and understanding the underlying biology of exosomes is opening up countless opportunities to co-opt the newly described biological processes for the purpose of engineering novel, purposefully-designed therapeutic entities.
Exocure Sweden AB is seeking to:
- Deploy the novel science underlying exosomes to design and test novel therapeutic candidates for serious unmet medical needs
- Develop know-how, create proprietary information, and submit patents to capture the IP therein, and ultimately,
- Further discover and characterize the biology underlying exosome processes.
Thus, ExocureTM is a platform company, developing the technology and methods to manipulate and manufacture vesicles, and then translate the exosome platform into specific therapeutics to be pursued for specific disease indications. In this way, Exocure will ensure successful outcomes for patients and clinicians to develop advanced medicines to achieve progress in otherwise incurable diseases.
We thank you for your interest in this innovative biotechnology opportunity.
Team
Jan Lötvall
Jan is an internationally acclaimed pioneer of exosome research. In 2007 he established a world-leading laboratory and research faculty at University of Gothenburg which he continues to lead. He is known for his ground-breaking research in the field, including a seminal paper in Nature Cell Biology in 2007. 2023-Lipid Prize Winner for ‘the discovery of exosomal shuttle of RNA between cells, 2016-2018 - Chief Scientist at Codiak BioSciences. 2013-ISEV Special Achievement Award for Exosome Science, 2011-2016 First President of the International Society for Extracellular Vesicles (www.isev.org).
Mats G Persson
Over 30 years experience in business development in pharma and medtech, latelly as Senior Vice President Business Development at SHL Group until 2019, when the company was sold to investors. SHL is a Swiss world-leading solutions provider in the design, development, and manufacturing of advanced delivery devices. Mats has been associated with Excoure since 2021, and is the Chairman of Exocure™ Sweden AB since 2023.
Kyong-su Park, PhD
Senior scientist: Kyong-su Park, PhD, has been researching exosomes since 2007, and has extensive know-how on developing innovative EV therapeutics. With Exocure since 2019.
Klementina Österberg
CEO of GUVentures, which provides management support to Exocure Sweden AB. She manages a broad team of business experts, project managers and financial staff supporting startups in Gothenburg.
Roger Olofsson Bagge
Clinical principal investigator, Professor Clinical Surgery, translational exosome research in the context of cancers.
Elisa Lazaro Ibañez
Advisor. Clinical principal investigator, Professor Clinical Surgery, translational exosome research in the context of cancers.